Dupilumab is designed to decrease type 2 inflammation in patients with bullous pemphigoid by targeting 2 key inflammatory cytokines, interleukin-4 and interleukin-13.

Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced. In the study, 106 patients were randomized to 300 mg of subcutaneous ...

The FDA based its approval on results from the LIBERTY-BP ADEPT (NCT04206553) phase 2 and 3 study, which found dupilumab effective for adults with moderate to severe bullous pemphigoid and met ...

Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the ...

Patients with bullous pemphigoid experienced symptom improvement with dupilumab treatment, according to a study.“Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases ...

Clinicians should consider dupilumab as a therapeutic option for bullous pemphigoid due to its ability to clear blistering and pruritus safely, according to a study.Bullous pemphigoid (BP) is a ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects ...

The phase 2/3 LIBERTY-BP ADEPT trial evaluated the safety and efficacy of dupilumab in 106 adults with moderate to severe bullous pemphigoid.

About Bullous Pemphigoid BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation that typically occurs in an elderly population.

Dupilumab for bullous pemphigoid induced by immune checkpoint inhibitors. Stephen W. Dusza , Gopa Iyer , Alina Markova Journal of Clinical Oncology 2025 43: 16_suppl , e24110-e24110 View Options ...

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD Regeneron Pharmaceuticals, Inc. Sat, Mar 8, 2025, 1:00 PM 16 min read ...